Go to content
argenx SE

argenx SE

Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.

Publicatie datum 03 mrt 2016 - 07:11
Statutaire naam argenx SE
Titel argenx to Host Conference Call & Webcast to Report Fourth Quarter Business Update and Full Year 2015 Financial Results on 11 March 2016
Bericht Breda, the Netherlands / Ghent, Belgium, 3 March 2016 - argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced it will host a conference call and audio webcast on Friday, 11 March 2016 at 3:00 pm CET (9:00 am ET) to discuss the 2015 financial results, as well as provide a fourth quarter business update.

Datum laatste update: 28 juli 2024